Peripheral Neuropathy: Can Regenerative Medicine Restore What Nerve Damage Takes Away?

When damaged nerves leave you with burning, numbness, or weakness in your hands and feet, conventional medicine manages symptoms. Regenerative research is investigating whether nerve function can actually be restored.

The Problem

When You Can't Trust Your Own Feet

Peripheral neuropathy begins insidiously. Perhaps you notice that bathwater feels less hot on your toes. Or a pins-and-needles sensation that doesn't go away. Or an ache in your feet at night that disrupts sleep.

As the condition progresses, the symptoms escalate:

• Numbness that creeps up from toes to feet to lower legs (the "stocking-glove" pattern)
• Burning pain that conventional painkillers barely touch
• Balance impairment — without sensation from your feet, proprioception fails, and falls become a serious risk
• Weakness — when motor nerves are affected, muscles waste and feet can drop
• Autonomic dysfunction — affected nerves controlling heart rate, blood pressure, and digestion

For the estimated 20 million Americans with peripheral neuropathy¹, the condition doesn't just cause pain — it steals independence. Falls become the leading fear. Driving becomes unsafe. Walking becomes treacherous.

⛔ Before Anything Else: Protecting Your Feet

**This is the part of neuropathy care that prevents the worst outcomes, and it is the part most often left

out.**

When sensation is reduced, injury stops hurting. **A stone in the shoe, a too-tight seam, a blister, a

scald in the bath, a small cut — none of them announce themselves.** They are found late, often infected,

sometimes after the bone underneath is already involved. **That sequence is how neuropathy leads to

amputation, and almost all of it is preventable.**

What the American Diabetes Association's position statement on diabetic neuropathy recommends⁹:

someone if you cannot see them easily

a deformity, or poor circulation. Ask for a podiatry referral

or previous ulceration warrants it

• ⚠️ Inspect your feet every day — tops, soles, between the toes, and the heels. Use a mirror or ask
• ⛔ Never walk barefoot, indoors or outdoors, and never in socks alone on hard floors
• Check inside your shoes before putting them on, every time
• Test bathwater with your elbow or a thermometer, not your foot
• Have your feet examined by a professional at least annually — more often if you have had an ulcer,
• Properly fitted footwear matters, and specialist or custom footwear is available if your foot shape

⚠️ Seek same-day medical review if you find any of these

Charcot arthropathy and it is an emergency

• Any new break in the skin, blister, crack or ulcer — however small, and even if it does not hurt
• Redness, warmth, swelling, or discharge from any part of the foot
• A change in the shape of the foot, or a hot swollen foot without an obvious wound — this can be
• A dark or black area of skin

⚠️ "It doesn't hurt" is not reassurance in neuropathy. It is the whole problem.

The Treatment Gap

The fundamental gap: nothing in the standard treatment arsenal rebuilds damaged nerve fibres or

restores lost sensation. Regenerative medicine research is investigating whether that gap can be closed.

⚠️ Two things follow from that, and the second is the one that matters most. First, the table above is

not a list of failures — glycaemic control, B12 correction and pain treatment all do real work. Second,

until sensation is genuinely restored, it is not restored — so the foot-protection routine above

continues regardless of any treatment you have, and **no result from any therapy on this page is a reason

to stop checking your feet.**

Understanding Peripheral Neuropathy

Types of Peripheral Neuropathy

The Biology of Nerve Damage

Peripheral nerves consist of:

1. Axons — the long nerve fibres that transmit electrical signals (some extending over 1 metre from spinal cord to toes)
2. Myelin sheath — the insulating layer (produced by Schwann cells) that enables rapid signal conduction
3. Endoneurium/perineurium — connective tissue that bundles and protects nerve fibres
4. Vasa nervorum — tiny blood vessels that supply oxygen and nutrients to the nerve

Neuropathy can involve:

• Demyelination — loss of the myelin sheath, slowing signal conduction (treatable; re-myelination possible)
• Axonal degeneration — destruction of the nerve fibre itself (more serious; regeneration slow and incomplete)
• Wallerian degeneration — complete nerve death distal to injury site (requires full regrowth)

Why Peripheral Nerves Can Regenerate (But Often Don't)

Unlike the brain and spinal cord, peripheral nerves retain the capacity for regeneration:

• Schwann cells survive and form "bands of Büngner" — aligned tubes that guide regrowing axons
• Growth cone formation — the cut end of an axon forms a growth cone that can navigate toward its target
• Regeneration rate: approximately 1-3 mm per day (about 1 inch per month)
• Growth factors: NGF, BDNF, GDNF, and NT-3 support regrowth

However, regeneration frequently fails because:

• In chronic neuropathy, the supportive Schwann cell environment degrades over time
• Endoneurial fibrosis (scarring) obstructs regrowth paths
• In metabolic neuropathies (diabetes), ongoing toxic conditions impair regeneration even as it occurs
• The regrowth distance from foot to spinal cord is enormous — axons may take 2-3 years to fully regenerate
• Target muscle and sensory receptors atrophy during prolonged denervation, reducing re-innervation success

This is where regenerative medicine enters: enhancing the nerve's own regenerative capacity by providing concentrated growth factors, reducing inflammation, and restoring the supportive environment that enables regrowth.

What the Research Says

PRP for Peripheral Neuropathy — Encouraging RCT Evidence

Anjayani et al. (2014) — Randomised Controlled Trial:

An RCT evaluating PRP perineural injection in 60 patients (30 per arm) with leprosy-related peripheral neuropathy³:

from mycobacterial infection and granulomatous inflammation — and sensory testing was at two weeks.

Diabetic neuropathy is a metabolic and microvascular disease with a different mechanism, and a

two-week sensory result in one condition is a reason to study the other, not evidence about it

• Sensory improvement: Significant improvement in two-point discrimination test (TPDT) and VAS pain scores in PRP group vs. control (p < 0.05)
• Rapid onset: Improvements documented at 2 weeks post-injection
• Safety: No serious adverse events
• ⚠️ Note the population and the timepoint. This trial was in leprosy neuropathy — nerve damage

Hassanien et al. (2020) — PRP for Diabetic Neuropathy RCT:

A randomised trial of 60 patients with type 2 diabetes and peripheral neuropathy of at least six months'

duration⁵. Group I received ultrasound-guided perineural PRP plus medical treatment; Group

II received medical treatment alone:

months (P ≤ 0.001)

axonal regrowth

• Pain and numbness (visual analogue scales): significant improvement in the PRP group at 1, 3 and 6
• Modified Toronto Clinical Neuropathy Score (mTCNS): improved in the PRP group versus control
• Mechanism proposed: PRP growth factors (PDGF, VEGF, NGF) may stimulate Schwann cell proliferation and

⚠️ Two limits worth knowing. The control group received medical treatment only — **there was no sham

injection**, so patients and assessors knew who had been injected, and the outcomes are subjective scores.

⛔ And this trial did not perform nerve conduction studies. Any claim that it showed improved nerve

conduction is not supported by the paper.

Sánchez et al. (2017) — PRP for Peripheral Nerve Regeneration (Review):

A comprehensive review of PRP applications in peripheral nerve regeneration, synthesising evidence from preclinical and clinical studies⁶:

• Growth factor delivery: PRP provides concentrated NGF, BDNF, VEGF, and PDGF that support Schwann cell proliferation and axonal regrowth
• Clinical applications: Evidence reviewed for compressive, traumatic, and metabolic neuropathies
• Applicability: Supports the rationale for PRP across multiple neuropathy types beyond diabetic neuropathy specifically

MSC Therapy — Phase I/II Data

Hur et al. (2016) — Allogeneic Placenta-Derived MSCs for Diabetic Neuropathy:

⚠️ Read the source description before the numbers. This work was presented as a conference abstract

at the American Diabetes Association Scientific Sessions (Diabetes 65, Supplement 1, A159)⁴.

It has no DOI, and searches of the biomedical literature return no peer-reviewed publication of it.

Conference abstracts are not peer-reviewed, report limited detail, and frequently differ from any paper

that eventually follows. Everything below should be read as preliminary and unverifiable.

A pilot Phase I/IIa study of allogeneic placenta-derived MSCs in 10 patients with diabetic peripheral

neuropathy⁴:

• Safety: Well-tolerated with no serious cell-related adverse events at 12 months
• Nerve conduction improvement: Significant improvement in tibial motor NCV and sural sensory NCV at 12 months
• Symptom scores: Improvement in Michigan Neuropathy Screening Instrument (MNSI) scores
• Pain reduction: Significant decrease in visual analogue scale (VAS) pain scores
• Skin biopsy: increased intraepidermal nerve fibre density (IENFD) in 2 of 3 biopsied patients

⚠️ What that is and is not. Three biopsies, from a ten-patient uncontrolled pilot, reported in a

conference abstract. **IENFD is a genuinely meaningful measure of small-fibre density — but two of three

samples moving in the right direction is a preliminary observation, not evidence of nerve regeneration.**

⛔ **Any statement that stem cell therapy has "demonstrated nerve regeneration" in humans rests on this,

and this cannot carry it.**

Mao et al. (2019) — Autologous BM-MNC for Diabetic Neuropathy:

A study of 168 patients with refractory diabetic peripheral neuropathy treated with intramuscular bone

marrow mononuclear cell transplantation⁷. ⚠️ **This was a single-arm study: every participant

received the treatment and was compared against their own baseline. There was no control group**, and in

a condition whose symptoms fluctuate, uncontrolled before-and-after comparisons overstate benefit:

• Toronto Clinical Scoring System: Improved from 12.55 to 9.68 at 1 month (p < 0.001), sustained through 36-month follow-up
• Motor NCV: Improved from 38.21 to 40.24-41.00 m/s (p < 0.001)
• Sensory NCV and action potentials: Also improved significantly at 3 and 12 months
• Safety: No treatment-associated adverse events

Growth Factor-Based Approaches

Apfel et al. (2000) — Recombinant NGF for Diabetic Neuropathy:

A Phase III RCT of subcutaneous recombinant human nerve growth factor (rhNGF) in 1,019 patients⁸:

48 weeks — this is the largest and most rigorous test of growth-factor supplementation for diabetic

neuropathy, and it did not meet its primary endpoint. It is sometimes argued that multi-factor

preparations such as PRP might succeed where a single recombinant factor failed. **That is a hypothesis

and no trial has tested it.** It should not be used to discount this result

• Primary endpoint (Neuropathy Impairment Score): Not statistically significant vs. placebo
• However: Significant improvement in Neuropathy Total Symptom Score and patient global assessment
• Key finding: Exogenous NGF improved symptoms but failed to demonstrate objective nerve regeneration at the doses and route used
• ⚠️ What a negative trial of this size means. 1,019 patients, randomised, placebo-controlled,

Summary Table

Treatment Approach at Our Clinic

Our Neuropathy Protocol

Candidacy

Best candidates:

• Diabetic peripheral neuropathy with documented nerve conduction impairment
• Idiopathic small-fibre neuropathy — unexplained burning pain in hands and feet
• Chemotherapy-induced peripheral neuropathy (CIPN) — post-treatment nerve damage
• Non-diabetic metabolic neuropathies (B12 deficiency, hypothyroid — once underlying cause corrected)
• Compressive neuropathies insufficiently responsive to standard treatment

Important considerations:

• Underlying cause must be identified and managed (continued uncontrolled diabetes will undermine regenerative benefit)
• Severe long-standing neuropathy with complete axonal loss has lower regenerative potential
• Hereditary neuropathies (Charcot-Marie-Tooth) — structural genetic conditions; regenerative approaches may support but cannot correct the genetic defect
• Active autoimmune neuropathy (CIDP, GBS) should be managed with immunotherapy before considering regenerative approaches

What to Expect: Our 7-Day Protocol

Day 1-2: Diagnostic Assessment

• Detailed neurological examination with neuropathy severity grading
• Nerve conduction studies (NCS) and electromyography (EMG)¹¹ — objective measurement of large-fibre function
• Quantitative sensory testing for small-fibre assessment
• Blood panel: HbA1c, B12, folate, thyroid function, inflammatory markers, heavy metals
• Discussion of diagnosis, prognosis, and realistic treatment expectations

Day 3-5: Treatment Phase

• PRP preparation and ultrasound-guided perineural injection (targeting affected nerve courses)
• IV NAD+ infusion (mitochondrial support for nerve energy metabolism)
• IV neurotrophic and anti-inflammatory protocols
• Balance and proprioceptive physiotherapy initiation
• Nutritional counselling for nerve health

Day 6-7: Planning & Follow-Up

• Review treatment response and expected timeline
• Home exercise programme for balance and lower limb strength
• Supplement and nutritional plan for nerve support
• Follow-up schedule: 6-week, 3-month, 6-month nerve conduction reassessment
• Planning for additional PRP sessions if indicated (typically 3 sessions total)

Recovery Expectations

Frequently Asked Questions

Q: Can peripheral neuropathy actually be reversed?

A: This depends on the type and severity. Demyelinating neuropathy (where the insulation around nerves is damaged but the nerve fibre itself is intact) has the best potential for recovery, as Schwann cells can re-myelinate nerve fibres. Mild-to-moderate axonal neuropathy can partially regenerate — peripheral nerves have this capacity, unlike central nerves. Severe, long-standing neuropathy with complete axonal loss and target organ atrophy has the lowest regenerative potential. Clinical trials with PRP and MSCs have shown measurable nerve conduction improvements, suggesting actual nerve repair³⁴.

Q: My neuropathy isn't from diabetes — does this research still apply?

A: ⚠️ Partly, and less than is often implied. The cellular machinery of nerve repair — Schwann

cell activation, axonal regrowth, angiogenesis — is broadly similar whatever the cause. **But the thing

damaging the nerve is not**, and that determines whether repair can keep up. Ongoing hyperglycaemia,

continued alcohol use, an untreated B12 deficiency or an active immune process will each undermine

regeneration while it is happening.

⚠️ The trial evidence is also thinner than the mechanism talk suggests: one small trial in leprosy

neuropathy and one in diabetic neuropathy. Results in one cause are not evidence in another.

⚖️ **The most useful thing on this page for you is therefore the first thing: get the cause identified and

treated.** For some causes — B12 deficiency, thyroid disease, some immune neuropathies — that is the

treatment, and it can work well.

Q: How long does nerve regeneration take?

A: Peripheral nerves regenerate at approximately 1-3 mm per day — about 1 inch per month. For neuropathy affecting the feet, the regenerating nerve fibres may need to travel a considerable distance from the lower leg. This means meaningful recovery typically takes 6-12 months, with continued improvement possible up to 24 months. This is why patience and consistent follow-up are essential.

Q: I've been told nothing can be done for my neuropathy — is that true?

A: The statement that "nothing can be done" typically means that conventional treatments cannot reverse nerve damage — which is accurate for current standard therapies. However, the emerging regenerative evidence suggests that enhancing the nerve's natural repair capacity may be possible. While this research is still developing, the PRP evidence in particular shows measurable nerve conduction improvements in controlled trials. A thorough assessment can determine whether your specific type and severity of neuropathy might benefit from these approaches.

Q: What about chemotherapy-induced neuropathy (CIPN)?

A: CIPN is a significant problem affecting 30-40% of patients receiving neurotoxic chemotherapy (taxanes, platinum compounds, vinca alkaloids). Research on regenerative approaches for CIPN is early but the mechanism is promising — chemotherapy damages nerve fibres, but the supportive architecture (Schwann cells, endoneurium) often remains intact, providing a framework for regeneration. PRP growth factors may help accelerate the nerve recovery that can occur naturally after chemotherapy completion.

Take the Next Step

Living with neuropathy? Want to know if regenerative treatment might help your situation?

• Take our 2-minute Health Assessment to tell us about your symptoms
• Book a Discovery Consultation to discuss your neuropathy with our specialist team

⚠️ **Whatever you decide about regenerative treatment, three things are worth doing first, and they are

free or nearly so:** get the cause of your neuropathy established, get your glucose and B12 checked and

treated, and start the daily foot routine described above. **Those are the interventions with the

strongest evidence behind them on this page.**